Blue Chip Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Blue Chip Partners's VRTX Position: Q2 2026 in Review
Blue Chip Partners increased its Vertex Pharmaceuticals (VRTX) stake by 26% in Q2 2026, buying an estimated $215K and bringing the position to 2,380 shares worth $1.18M. The position accounts for 0.07% of the portfolio, ranked #89.
Blue Chip Partners first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Blue Chip Partners held 2,380 shares of Vertex Pharmaceuticals worth $1.18M as of Q2 2026.
- Blue Chip Partners bought 485 Vertex Pharmaceuticals shares in Q2 2026, an estimated $215K.
- Vertex Pharmaceuticals made up 0.07% of Blue Chip Partners's portfolio in Q2 2026, its #89 holding.
- Blue Chip Partners first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Blue Chip Partners's 13F filing for Q2 2026, filed 14 Aug 2026.